HOPE IS ON THE HORIZON
Using metabolomics and machine learning Olaris ® develops in vitro diagnostics that empower patients, providers and biopharma to pursue the most effective treatments.
We get the right therapy to the right patient at the right time.
"By identifying a person’s “biomarkers of response” (BoR), we can determine which patients will benefit from a specific therapy to optimize outcomes and reduce adverse events."
Dr. Elizabeth O’Day, CEO & Founder, Olaris, Inc
WHY WE NEED
Precision medicine uses a patient's molecular makeup to guide individual health decisions. In our blood are biomarkers (DNA, RNA, protein and metabolites) that make us who we are as individuals. These biomarkers help us determine why certain people are susceptible to certain diseases, while others are not. Further, biomarkers explain why if two people get the same disease and are treated with the exact same drug, one person, may see promising results, while the other may see little or no effect. Or worse, in some cases, they may be harmed by that drug. Unfortunately, we live in a world of "imprecision medicine" where in most cases the number of patients who do not benefit from a specific drug greatly outnumber the number of patients who do. BoRs can avoid these harmful effects and useless drug prescriptions.
PERCENTAGE OF THE PATIENT POPULATION FOR WHICH A PARTICULAR DRUG IS EFFECTIVE
Spear, B.B., et al., (2001) Clinical Trends in Molecular Medicine. 7(5); 201-204
WE GET THE RIGHT DRUG, TO THE RIGHT PATIENT, AT THE RIGHT TIME
To create a superior quality healthcare system by producing “Biomarkers of Response” (BoR) that empower PATIENTS, PROVIDERS, and PAYERS to ensure optimal treatment decisions.